Influence of toremifene on the endocrine regulation in breast cancer patients
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 30 (2), 154-158
- https://doi.org/10.1016/0959-8049(94)90077-9
Abstract
In a combined phase I-II study, the hormonal effects of toremifene (TOR) were investigated in 30 patients. Half of the patients received continuous therapy of TOR 60 mg and half 300 mg of TOR orally daily. Serum concentrations of oestradiol (E2), progesterone (PROG), testosterone (TE), follicle stimulating hormone (FSH), luteinising hormone (LH), prolactin (PRL), human growth hormone (hGH) and sex hormone binding globulin (SHBG) were monitored prior to the treatment and at the second, sixth, eighth and twelfth weeks. The influence of TOR upon the hypothalamo-hypophyseal axis was investigated by the TRH (thyroid-stimulating hormone releasing hormone) functional test using 400 micrograms intravenous injection of TRH for stimulation of PRL secretion. The concentration of E2 decreased during the TOR therapy with 60 mg and 300 mg causing 82 and 71% decreases, respectively (non-significant). PRL was significantly (P < 0.001) suppressed. Both these effects reflect the anti-oestrogenic action of TOR. SHBG increased significantly at both doses of TOR, probably due to a direct oestrogen-like effect of TOR in the liver. TE decreased as a consequence of the elevated SHBG. The TRH-induced PRL release was suppressed by both doses of TOR. There were 17 and 27% reductions at 12 weeks in the 60 and 300 mg groups, respectively. Other hormones measured were not significantly affected by TOR. The hormonal effects of 60 and 300 mg doses of TOR did not differ significantly. Anti-oestrogenic (i.e. decrease of E2), and partially oestrogenic (i.e. increase of SHBG) properties as well as the antiprolactinic effects of TOR may have an overall beneficial effect in the clinical management of breast cancer patients.Keywords
This publication has 17 references indexed in Scilit:
- Phase II trials with toremifene in advanced breast cancer: A reviewBreast Cancer Research and Treatment, 1990
- Safety and efficacy of toremifene in breast cancer patients. A phase II studyJournal of Steroid Biochemistry, 1990
- Effect of toremifene in breast cancer patients. Preliminary communicationJournal of Steroid Biochemistry, 1990
- Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Hormonal Changes during a Prolonged Tamoxifen Treatment in Patients with Advanced Breast CancerOncology, 1986
- Oestrogen-like effects of tamoxifen on the concentration of proteins in plasmaActa Endocrinologica, 1981
- INCREASES IN STEROID BINDING GLOBULINS INDUCED BY TAMOXIFEN IN PATIENTS WITH CARCINOMA OF THE BREASTJournal of Endocrinology, 1978
- Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.BMJ, 1977
- EFFECT OF THE ANTI-OESTROGEN TAMOXIFEN ON PLASMA LEVELS OF LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE, PROLACTIN, OESTRADIOL AND PROGESTERONE IN NORMAL PRE-MENOPAUSAL WOMENJournal of Endocrinology, 1976
- INHIBITION OF OESTROGEN-STIMULATED PROLACTIN RELEASE BY ANTI-OESTROGENSJournal of Endocrinology, 1975